{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T20:02:22Z","timestamp":1775246542719,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13014-017-0873-1","type":"journal-article","created":{"date-parts":[[2017,8,15]],"date-time":"2017-08-15T08:12:49Z","timestamp":1502784769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study"],"prefix":"10.1186","volume":"12","author":[{"given":"Ja Kyung","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ik Jae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Moon","family":"Joo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang-Hun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun-Suk","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong-Sik","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Joo","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonsoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Il","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwan Sik","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,15]]},"reference":[{"issue":"5","key":"873_CR1","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.bpg.2014.08.007","volume":"28","author":"C Bosetti","year":"2014","unstructured":"Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol. 2014;28(5):753\u201370.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"5 Suppl 1","key":"873_CR2","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1053\/j.gastro.2004.09.011","volume":"127","author":"FX Bosch","year":"2004","unstructured":"Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5 Suppl 1):S5\u2013S16.","journal-title":"Gastroenterology"},{"issue":"8","key":"873_CR3","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.ejso.2008.01.031","volume":"34","author":"J Sakata","year":"2008","unstructured":"Sakata J, Shirai Y, Wakai T, et al. Preoperative predictors of vascular invasion in hepatocellular carcinoma. Eur J Surg Oncol. 2008;34(8):900\u20135.","journal-title":"Eur J Surg Oncol"},{"issue":"19","key":"873_CR4","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1002\/cncr.25960","volume":"117","author":"K Uchino","year":"2011","unstructured":"Uchino K, Tateishi R, Shiina S, et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer. 2011;117(19):4475\u201383.","journal-title":"Cancer"},{"issue":"9822","key":"873_CR5","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","volume":"379","author":"A Forner","year":"2012","unstructured":"Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245\u201355.","journal-title":"Lancet"},{"issue":"4","key":"873_CR6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378\u201390.","journal-title":"N Engl J Med"},{"issue":"1","key":"873_CR7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25\u201334.","journal-title":"Lancet Oncol"},{"issue":"3","key":"873_CR8","first-page":"267","volume":"9","author":"KLCSG-NCC","year":"2015","unstructured":"KLCSG-NCC. Korea practice guideline for the management of Hepatocellular carcinoma. Gut Liver. 2015;9(3):267\u2013317.","journal-title":"Gut Liver"},{"issue":"3","key":"873_CR9","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000367766","volume":"5","author":"HC Park","year":"2016","unstructured":"Park HC, Yu JI, Cheng JC, et al. Consensus for radiotherapy in Hepatocellular carcinoma from the 5th Asia-Pacific primary liver cancer expert meeting (APPLE 2014): current practice and future clinical trials. Liver Cancer. 2016;5(3):162\u201374.","journal-title":"Liver Cancer"},{"issue":"Suppl 1","key":"873_CR10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000333275","volume":"81","author":"IJ Lee","year":"2011","unstructured":"Lee IJ, Seong J. Radiotherapeutic strategies in the management of hepatocellular carcinoma. Oncology. 2011;81(Suppl 1):123\u201333.","journal-title":"Oncology"},{"issue":"5","key":"873_CR11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/cncr.23684","volume":"113","author":"KH Han","year":"2008","unstructured":"Han KH, Seong J, Kim JK, et al. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer. 2008;113(5):995\u20131003.","journal-title":"Cancer"},{"issue":"4","key":"873_CR12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000227477","volume":"52","author":"H Toyoda","year":"1995","unstructured":"Toyoda H, Nakano S, Kumada T, et al. The efficacy of continuous local arterial infusion of 5-fluorouracil and Cisplatin through an implanted reservoir for severe advanced Hepatocellular carcinoma. Oncology. 1995;52(4):295\u20139.","journal-title":"Oncology"},{"issue":"3","key":"873_CR13","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/cncr.10694","volume":"95","author":"E Ando","year":"2002","unstructured":"Ando E, Tanaka M, Yamashita F, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer. 2002;95(3):588\u201395.","journal-title":"Cancer"},{"issue":"3","key":"873_CR14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/jso.10116","volume":"80","author":"T Itamoto","year":"2002","unstructured":"Itamoto T, Nakahara H, Tashiro H, et al. Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J Surg Oncol. 2002;80(3):143\u20138.","journal-title":"J Surg Oncol"},{"issue":"2","key":"873_CR15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1148\/radiology.148.2.6306721","volume":"148","author":"R Yamada","year":"1983","unstructured":"Yamada R, Sato M, Kawabata M, et al. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology. 1983;148(2):397\u2013401.","journal-title":"Radiology"},{"key":"873_CR16","doi-asserted-by":"crossref","unstructured":"Kothary N, Weintraub JL, Susman J, et al. Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk. J Vasc Interv Radiol. 2007;18(12):1517\u201326.","DOI":"10.1016\/j.jvir.2007.07.035"},{"issue":"1","key":"873_CR17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/01.RVI.0000195074.43474.2F","volume":"17","author":"JM Kiely","year":"2006","unstructured":"Kiely JM, Rilling WS, Touzios JG, et al. Chemoembolization in patients at high risk: results and complications. J Vasc Interv Radiol. 2006;17(1):47\u201353.","journal-title":"J Vasc Interv Radiol"},{"issue":"12","key":"873_CR18","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/01.RVI.0000182185.47500.7A","volume":"16","author":"CS Georgiades","year":"2005","unstructured":"Georgiades CS, Hong K, D'Angelo M, et al. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol. 2005;16(12):1653\u20139.","journal-title":"J Vasc Interv Radiol"},{"issue":"6","key":"873_CR19","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3349\/ymj.2014.55.6.1489","volume":"55","author":"IJ Lee","year":"2014","unstructured":"Lee IJ, Kim JW, Han KH, et al. Concurrent chemoradiotherapy shows long-term survival after conversion from locally advanced to resectable hepatocellular carcinoma. Yonsei Med J. 2014;55(6):1489\u201397.","journal-title":"Yonsei Med J"},{"issue":"1","key":"873_CR20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijrobp.2008.04.035","volume":"73","author":"IJ Lee","year":"2009","unstructured":"Lee IJ, Seong J, Shim SJ, et al. Radiotherapeutic parameters predictive of liver complications induced by liver tumor radiotherapy. Int J Radiat Oncol Biol Phys. 2009;73(1):154\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"873_CR21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52\u201360.","journal-title":"Semin Liver Dis"},{"issue":"6","key":"873_CR22","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/jrr\/rrt034","volume":"54","author":"H Cha","year":"2013","unstructured":"Cha H, Yoon HI, Lee IJ, et al. Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-confined hepatocellular carcinoma. J Radiat Res. 2013;54(6):1069\u201377.","journal-title":"J Radiat Res"},{"issue":"1","key":"873_CR23","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4143\/crt.2014.276","volume":"48","author":"HI Yoon","year":"2016","unstructured":"Yoon HI, Song KJ, Lee IJ, et al. Clinical benefit of hepatic arterial infusion concurrent Chemoradiotherapy in locally advanced Hepatocellular carcinoma: a propensity score matching analysis. Cancer Res Treat. 2016;48(1):190\u20137.","journal-title":"Cancer Res Treat"},{"issue":"5","key":"873_CR24","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3349\/ymj.2016.57.5.1276","volume":"57","author":"DH Han","year":"2016","unstructured":"Han DH, Joo DJ, Kim MS, et al. Living donor liver transplantation for advanced Hepatocellular carcinoma with portal vein tumor thrombosis after concurrent Chemoradiation therapy. Yonsei Med J. 2016;57(5):1276\u201381.","journal-title":"Yonsei Med J"},{"issue":"10","key":"873_CR25","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.3748\/wjg.v17.i10.1267","volume":"17","author":"TJ Vogl","year":"2011","unstructured":"Vogl TJ, Nour-Eldin NE, Emad-Eldin S, et al. Portal vein thrombosis and arterioportal shunts: effects on tumor response after chemoembolization of hepatocellular carcinoma. World J Gastroenterol. 2011;17(10):1267\u201375.","journal-title":"World J Gastroenterol"},{"issue":"12","key":"873_CR26","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1007\/s00535-010-0278-5","volume":"45","author":"K Yamamoto","year":"2010","unstructured":"Yamamoto K, Imamura H, Matsuyama Y, et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol. 2010;45(12):1272\u201382.","journal-title":"J Gastroenterol"},{"issue":"8","key":"873_CR27","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1358\/dnp.2010.23.8.1444236","volume":"23","author":"G Bertino","year":"2010","unstructured":"Bertino G, Ardiri AM, Calvagno GS, et al. Prognostic and diagnostic value of des-gamma-carboxy prothrombin in liver cancer. Drug News Perspect. 2010;23(8):498\u2013508.","journal-title":"Drug News Perspect"},{"issue":"3","key":"873_CR28","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1478-3231.2010.02368.x","volume":"31","author":"BK Kim","year":"2011","unstructured":"Kim BK, Ahn SH, Seong JS, et al. Early alpha-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. Liver Int. 2011;31(3):369\u201376.","journal-title":"Liver Int"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-017-0873-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T08:17:15Z","timestamp":1570004235000},"score":1,"resource":{"primary":{"URL":"http:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-017-0873-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,15]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["873"],"URL":"https:\/\/doi.org\/10.1186\/s13014-017-0873-1","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,15]]},"article-number":"133"}}